GrossRAJohnstonKC. Levels of Evidence: Taking Neurology to the next level. Neurology2009; 72: 8–10.
2.
GoodinDSRederAT. Evidence-based medicine: promise and pitfalls. Mult Scler2102; [in press].
3.
FrenchJGronsethG. Lost in a jungle of evidence: We need a compass. Neurology2008; 71: 1634–1638.
4.
SteinMSLiuYGrayOMBakerJEKolbeSCDitchfieldMR. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011; 77: 1611–1618.
5.
GoodinDSRederATEbersGCCutterGKremenchutzkyMOgerJ. Survival in MS A randomized cohort study 21 years after the start of the pivotal INNβ-1b trial. Neurology2012; 78: 1315–1322.
6.
AAN (American Academy of Neurology). Clinical Practice Guideline Process Manual, 2011 Ed. St. Paul, MN: The American Academy of Neurology; 2011.
7.
SchultzKFAltmanDGMoherD. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Ann Intern Med2010; 152; 1–8.
GoodinDSRederAT. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology1993; 43: 655–661.
10.
MoyeLA. P-Value Interpretation and Alpha Allocation in Clinical Trials. Annals of Epidemiology1998; 8: 351–357.
11.
McGauranNWieselerBKreisJSchülerYBKölschHKaiserT. Reporting bias in medical research - a narrative review. Trials2010; 11; 1–15.
12.
AbdiH. Bonferroni and Šidák corrections for multiple comparisons. In: SalkindNJ editor. Encyclopedia of Measurement and Statistics. Thousand Oaks, CA: Sage. 2007. http://www.utdallas.edu/~herve/Abdi-Bonferroni2007-pretty.pdf. [Accessed April 16, 2012.]
